Irinotecan (Iri) in combination with high-dose infusional (HDI) 5FU/FA either weekly or bi-weekly: evidence of survival advantage and quality of life (QoL) improvement in metastatic colorectal cancer (MCRC)

✍ Scribed by P. Rougier; D. Cunningham; A.D. Roth; J.R. Germa; R.D. James; P. Karasek; P. Jandik; T. Iveson; J. Carmichael; G. Gruia; M. Alakl; D. Sibaud; J.Y. Douillard

• Book ID: 117667189
• Publisher: Elsevier Science
• Year: 1999
• Tongue: English
• Weight: 117 KB
• Volume: 35
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/s0959-8049(99)80639-x